Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Informing Data to Care: Contacting Persons Sampled for the Medical Monitoring Project.

Beer L, Bosh KA, Chowdhury PP, Craw J, Nyaku MA, Luna-Gierke RE, Sanders CC, Shouse RL.

J Acquir Immune Defic Syndr. 2019 Sep 1;82 Suppl 1:S6-S12. doi: 10.1097/QAI.0000000000001997.

PMID:
31425389
2.

Behavioral and clinical characteristics of persons receiving medical care for HIV infection - Medical Monitoring Project, United States, 2009.

Blair JM, Fagan JL, Frazier EL, Do A, Bradley H, Valverde EE, McNaghten A, Beer L, Zhang S, Huang P, Mattson CL, Freedman MS, Johnson CH, Sanders CC, Spruit-McGoff KE, Heffelfinger JD, Skarbinski J; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC.

MMWR Suppl. 2014 Jun 20;63(5):1-22.

PMID:
24941443
3.

BetalasEN: microdilution panel for identifying beta-lactamases present in isolates of Enterobacteriaceae.

Sanders CC, Ehrhardt AF, Moland ES, Thomson KS, Zimmer B, Roe DE.

J Clin Microbiol. 2002 Jan;40(1):123-7.

4.

Potential impact of the VITEK 2 system and the Advanced Expert System on the clinical laboratory of a university-based hospital.

Sanders CC, Peyret M, Moland ES, Cavalieri SJ, Shubert C, Thomson KS, Boeufgras JM, Sanders WE Jr.

J Clin Microbiol. 2001 Jul;39(7):2379-85.

5.

Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.

Lister PD, Sanders CC.

J Antimicrob Chemother. 2001 Jun;47(6):811-8.

PMID:
11389113
6.

Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones.

Sanders CC.

Clin Infect Dis. 2001 Mar 15;32 Suppl 1:S1-8. Review.

PMID:
11249822
7.

Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

Sanders CC, Peyret M, Moland ES, Shubert C, Thomson KS, Boeufgras JM, Sanders WE Jr.

J Clin Microbiol. 2000 Feb;38(2):570-4.

8.

A pilot study of antibiotic cycling in a hematology-oncology unit.

Dominguez EA, Smith TL, Reed E, Sanders CC, Sanders WE Jr.

Infect Control Hosp Epidemiol. 2000 Jan;21(1 Suppl):S4-8.

PMID:
10654628
9.

Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.

Pong A, Thomson KS, Moland ES, Chartrand SA, Sanders CC.

J Antimicrob Chemother. 1999 Nov;44(5):621-7.

PMID:
10552978
10.

Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae.

Hanson ND, Sanders CC.

Curr Pharm Des. 1999 Nov;5(11):881-94. Review.

PMID:
10539994
11.

Molecular characterization of a multiply resistant Klebsiella pneumoniae encoding ESBLs and a plasmid-mediated AmpC.

Hanson ND, Thomson KS, Moland ES, Sanders CC, Berthold G, Penn RG.

J Antimicrob Chemother. 1999 Sep;44(3):377-80.

PMID:
10511405
12.

In-vitro activity of levofloxacin against Streptococcus pneumoniae with various levels of penicillin resistance.

Thomson KS, Chartrand SA, Sanders CC, Block SL.

J Antimicrob Chemother. 1999 Jun;43 Suppl C:15-9.

PMID:
10404332
13.

Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.

Lister PD, Sanders CC.

J Antimicrob Chemother. 1999 Jan;43(1):79-86.

PMID:
10381104
15.
17.
18.

The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.

Thomson KS, Sanders CC.

J Antimicrob Chemother. 1998 Aug;42(2):179-87.

PMID:
9738835
20.

Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa.

Lister PD, Sanders WE Jr, Sanders CC.

Antimicrob Agents Chemother. 1998 Jul;42(7):1610-9.

21.
22.

Development of quinolone-resistant Campylobacter fetus bacteremia in human immunodeficiency virus-infected patients.

Meier PA, Dooley DP, Jorgensen JH, Sanders CC, Huang WM, Patterson JE.

J Infect Dis. 1998 Apr;177(4):951-4.

PMID:
9534967
23.

Plasmid-mediated resistance to expanded-spectrum cephalosporins among Enterobacter aerogenes strains.

Pitout JD, Thomson KS, Hanson ND, Ehrhardt AF, Coudron P, Sanders CC.

Antimicrob Agents Chemother. 1998 Mar;42(3):596-600.

24.

Structure-activity studies of quinolone-penems in genetically defined strains of Escherichia coli.

Ehrhardt AF, Sanders CC.

Antimicrob Agents Chemother. 1997 Nov;41(11):2570-2.

26.

Penicillin-binding proteins and induction of AmpC beta-lactamase.

Sanders CC, Bradford PA, Ehrhardt AF, Bush K, Young KD, Henderson TA, Sanders WE Jr.

Antimicrob Agents Chemother. 1997 Sep;41(9):2013-5.

27.
29.

Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli.

Pitout JD, Sanders CC, Sanders WE Jr.

Am J Med. 1997 Jul;103(1):51-9. Review.

PMID:
9236486
30.

Circumventing antibiotic resistance in specialized hospital units.

Sanders WE, Sanders CC.

Clin Microbiol Infect. 1997 Apr;3(2):272. No abstract available.

31.

Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Sanders WE Jr, Sanders CC.

Clin Microbiol Rev. 1997 Apr;10(2):220-41. Review.

33.

Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.

Thomson KS, Chartrand SA, Sanders CC, Block SL.

Antimicrob Agents Chemother. 1997 Feb;41(2):478-80.

35.

Beta-lactamases and detection of beta-lactam resistance in Enterobacter spp.

Pitout JD, Moland ES, Sanders CC, Thomson KS, Fitzsimmons SR.

Antimicrob Agents Chemother. 1997 Jan;41(1):35-9.

36.

Detection of extended-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test.

Sanders CC, Barry AL, Washington JA, Shubert C, Moland ES, Traczewski MM, Knapp C, Mulder R.

J Clin Microbiol. 1996 Dec;34(12):2997-3001.

38.

Sequencing and analysis of four new Enterobacter ampD Alleles.

Ehrhardt AF, Sanders CC, Romero JR, Leser JS.

Antimicrob Agents Chemother. 1996 Aug;40(8):1953-6.

39.

Cycling of antibiotics: an approach to circumvent resistance in specialized units of the hospital.

Sanders WE, Sanders CC.

Clin Microbiol Infect. 1996 Jun;1(4):223-225. No abstract available.

40.
41.

Piperacillin/tazobactam: a critical review of the evolving clinical literature.

Sanders WE Jr, Sanders CC.

Clin Infect Dis. 1996 Jan;22(1):107-23. Review.

PMID:
8824974
42.

Novel plasmid-mediated beta-lactamases in enterobacteriaceae: emerging problems for new beta-lactam antibiotics.

Thomson KS, Prevan AM, Sanders CC.

Curr Clin Top Infect Dis. 1996;16:151-63. Review. No abstract available.

PMID:
8714252
43.

Cefepime : The Last Generation or the First Enhanced-Potency Broad Spectrum Cephalosporin?

Sanders CC, Moland ES.

Clin Drug Investig. 1995 Dec;10(6):344-54. doi: 10.2165/00044011-199510060-00005.

PMID:
27519336
44.

New variant of TEM-10 beta-lactamase gene produced by a clinical isolate of proteus mirabilis.

Palzkill T, Thomson KS, Sanders CC, Moland ES, Huang W, Milligan TW.

Antimicrob Agents Chemother. 1995 May;39(5):1199-200.

47.

Resistance to antibacterial agents.

Sanders CC, Sanders WE Jr.

Adv Exp Med Biol. 1995;390:15-23. Review. No abstract available.

PMID:
8718599
48.

Fluoroquinolone resistance in staphylococci: new challenges.

Sanders CC, Sanders WE Jr, Thomson KS.

Eur J Clin Microbiol Infect Dis. 1995;14 Suppl 1:S6-11. Review.

PMID:
7729471
49.

Dissociated resistance among fluoroquinolones.

Thomson KS, Sanders CC.

Antimicrob Agents Chemother. 1994 Sep;38(9):2095-100.

50.

USA resistance patterns among UTI pathogens.

Thomson KS, Sanders WE, Sanders CC.

J Antimicrob Chemother. 1994 May;33 Suppl A:9-15. Review.

PMID:
7928840

Supplemental Content

Loading ...
Support Center